Work

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Year: 2017

Type: article

Abstract: < .05). Early POD within 2 years of first-line therapy is a robust clinical prognostic factor for inferior OS in patients with CLL. The Connect CLL Registry was registered at www.clinicaltrials.gov as #NCT01081015.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017011262

Authors: Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers

Institutions: National Institutes of Health, National Cancer Institute, Dana-Farber Cancer Institute, Endeavor Health, Mayo Clinic, Columbia University Irving Medical Center, Abramson Cancer Center, University of Pennsylvania, Cardinal Health (United States), Celgene (United States), Willamette Valley Cancer Institute and Research Center, Emory University, Winship Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funder: Celgene

OpenAlex ID: W2768375863

FWCI: 0.669

Cites: 36

Cited by: 14

Related to: 10